Promising Test for Dendreon's Prostate Cancer Drug

New York Times by Andrew Pollack | Apr. 14, 2009 (Special Report)

A prostate cancer drug developed by the Seattle biotechnology company Dendreon prolonged the lives of men in a decisive clinical trial, the company announced Tuesday morning.

The widely anticipated results could pave the way for the drug, called Provenge, to become the first so-called therapeutic cancer “vaccine” to win approval in the United States after numerous failures of such drugs.

“This looks like a proof of concept that ... Full Story »

Posted by Christina Wootton

More Info

Tags Help
Subjects: Health
Topics: Cancer
Member Tags: biotechnology, drug
Editorial Help
Posted by: Posted by Christina Wootton - Apr 14, 2009 - 6:21 PM PDT
Reviewed by: Christina Wootton (review)
Content Type: Article
Edit Lock: This story can be edited
Edited by: Christina Wootton - Apr 14, 2009 - 6:21 PM PDT

Reviews

Show All Comments
Show All | Notes | Comments | Quotes | Links
Christina Wootton
3.8
 by Christina Wootton - Apr. 14, 2009

This piece is a presentation of the groundbreaking prostate cancer drug that has the potential to greatly benefit the vast majority of those individuals suffering from prostate cancer. The well-written publication gives numbers, quotes, and support for providing knowledge regarding this topic to the general public. It offers scientific evidence and explanation to how the drug works, giving the story a contextual basis for its newsworthy topic.

Christina posted this story.
See Full Review » (11 answers)

Comments on this story Help (BETA)

Sort by: Oldest | Newest Hide All Replies
NT Rating | My Rating

Ratings

3.8

not enough reviews
from 1 review (10% confidence)
Quality
3.9
Facts
4.0
Fairness
4.0
Sourcing
3.0
Style
4.0
Context
4.0
Depth
5.0
Enterprise
4.0
Relevance
3.0
Popularity
3.4
Recommendation
3.0
Credibility
4.0
# Reviews
1.0
# Views
5.0
# Likes
1.0
# Emails
1.0
More
How our ratings work »

Topics

Health | Cancer
(See these related stories.)

Links Help

No links yet. Please review this story to add some!